Showing results (1961-1970 of 2,369) with videos related to

Sort By:
Pageof 237
Minerva Urology and Nephrology|April 23, 2026
Detrimental effect of delayed or incomplete BCG protocols administration after trans-urethral tumor resection in patients with non-muscle-invasive bladder cancer: a systematic reviewEttore DI Trapani, Arturo Lo Giudice, Elio Mazzone, et al.
International Urology and Nephrology|June 18, 2026
Penile curvature surgery in contemporary practice: effectiveness, satisfaction, and complications after corporoplasty in a tertiary referral centerJosvany-René Sánchez-Curbelo, Massimiliano Raffo, Gibrán Castro Treviño, et al.
The Prostate|June 23, 2026
Years of Life Lost From Metastatic Prostate Cancer According to Treatment Era and Race/EthnicityLeonardo Quarta, Michele Petix, Maximilian Filzmayer, et al.
Urologic Oncology|June 20, 2021
A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02Andrea Necchi, Alberto Martini, Daniele Raggi, et al.
World Journal of Urology|February 3, 2019
Should partial nephrectomy be considered "elective" in patients with stage 2 chronic kidney disease? A comparative analysis of functional and survival outcomes after radical and partial nephrectomyZachary A Hamilton, Umberto Capitanio, Brian R Lane, et al.
Journal of the National Cancer Institute|January 15, 2009
Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancerVitaly Margulis, Yair Lotan, Pierre I Karakiewicz, et al.
BJU International|April 13, 2007
Health-insurance status is a determinant of the stage at presentation and of cancer control in European men treated with radical prostatectomy for clinically localized prostate cancerAndrea Gallina, Pierre I Karakiewicz, Felix K-H Chun, et al.
The Journal of Urology|November 16, 2010
The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE studyGerald L Andriole, David Bostwick, Otis W Brawley, et al.
European Urology Focus|November 11, 2020
Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical CystectomyLaura Marandino, Antonella Capozza, Marco Bandini, et al.
Seminars in Oncology|May 24, 2022
Cancer-specific mortality in patients with non-metastatic renal cell carcinoma who have undergone a nephrectomy and are eligible for adjuvant pembrolizumabRocco S Flammia, Benedikt Hoeh, Lukas Hohenhorst, et al.
Pageof 237